Mein Warenkorb

Human CD37 Full Length Protein (VLP)

User Reviews
Product Number/Spec
Price
Menge
CD7-H52P4-20ug
$620.00
CD7-H52P4-100ug
$1235.00
CD7-H52P4-500ug (250ug X 2)
$4305.00
ETA of in-stock products:2 business days
Gesamtanzahl Product Amount$ 0

Product Details

  • Application

    1. Immunization
    2. Cell based assay (FACS or functional assay)
    3. Screening (ELISA)
  • Synonyms

    CD37, Tspan-26, TSPAN26

  • Source

    Human CD37 Full Length Protein (VLP) (CD7-H52P4) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Arg 281 (Accession # P11049).

    Predicted N-terminus: Met 1

  • Molecular Characterization

    *The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

    2. Synthesis Process

      Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SEC-HPLC.

  • Formulation

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

    Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Kunden haben auch angesehen

Data Display

  • SEC-HPLC

    CD37 SEC-HPLC

    The purity of Human CD37 Full Length Protein (VLP) (Cat. No. CD7-H52P4) was greater than 95% as determined by SEC-HPLC.

  • Bioactivity-ELISA

     CD37 ELISA

    Immobilized Human CD37 Full Length Protein (VLP) (Cat. No. CD7-H52P4) at 5 μg/mL (100 μL/well) can bind Anti-CD37 antibody (Naratuximab), Human IgG1 with a linear range of 0.1-0.8 ng/mL (QC tested).

    Protocol
  • Identity-DLS

     CD37 DLS

    The mean peak Radius of VLP is 50-80 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

User Reviews
Publish Comment

Background Introduction

A tetraspanin protein highly restricted to the B-cell lineage and a validated target in B-cell malignancies. CD37 modulates integrin signaling and cell adhesion. Therapeutics include antibody-drug conjugates (naratuximab emtansine) and CAR-T cells designed to treat Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.

Frontier Progress

 
Drug Development Progress
  • English Name:

    Leukocyte antigen CD37

  • Category:

  • Listed Drugs Count:

    0 Details

  • Clinical Drugs Count:

    8 Details

  • Highest R&D Stage:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Kunden haben auch angesehen
  • Data Display
  • User Reviews
  • Hintergrund
Kontaktieren Sie uns